Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites

HIV Medicine

Volumn 11, Issue 9, 2010, Pages 554-564

  Belloso, W H ^a   Orellana, L C ^b   Grinsztejn, B ^c   Madero, J S ^d   La Rosa, A ^e   Veloso, V G ^c   Sanchez, J ^e   Ismerio Moreira, R ^c   Crabtree Ramirez, B ^d   Garcia Messina, O ^f   Lasala, M B ^g   Peinado, J ^e   Losso, M H ^h  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^b INSTITUTO DE CÁLCULO   (Argentina)

^c Funda??o Oswaldo Cruz   (Brazil)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e INMENSA   (Peru)

^f Hosp Gen Agudos Parmenio T Pinero   (Argentina)

^g HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^h HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

AIDS; Cardiovascular disease; CD4 cell lymphocyte count; Cohort studies; Liver diseases; Neoplasms

Indexed keywords

ACUTE KIDNEY FAILURE; ADULT; ALCOHOL ABUSE; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR EFFECT; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LIVER FAILURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; RENAL INSUFFICIENCY; SOUTH AMERICA;

EID: 77956409943     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00824.x     Document Type: Article

References (36)

1. Mocroft A, Ledergerber B, Katlama C. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
2. Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV Ther 2006, 2:36-38.
3. Mocroft A, Phillips AN, Lundgren JD. HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med 2004, 140:578-579.
4. Short-term risk of AIDS according to current CD4 cell cell count and viral load in antiretroviral drug-naïve individuals and in those treated in the monotherapy era. AIDS 2004, 18:51-58. CASCADE Collaboration.
5. Egger M, May M, Chene G. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
6. Lau B, Gange S, Moore RD. Risk of non-AIDS related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4 cell+counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007, 44:179-187.
7. Weber R, Sabin CA, Friis-Møller N. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
8. Smit C, Geskus R, Walker S. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006, 20:741-749.
9. Palella FJ, Baker RK, Moorman AC. Mortality in the highly active antiretroviral therapy era. Changing causes of death and disease in the HIV outpatient study. J Acquir Immun Defic Syndr 2006, 43:27-34.
10. Baker JV, Peng G, Rapkin J. CD4 cell+count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008, 22:841-848.
11. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Intern Med 2006, 166:1632-1641. D:A:D Study Group.
12. Monforte A, Abrams D, Pradier C. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008, 22:2143-2153.
13. El-Sadr WM, Lundgren JD, Neaton JD. CD4+count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296. for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group
14. Emery S, Neuhaus JA, Phillips AN. Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART Study. J Infect Dis 2008, 197:1133-1144. for the Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
15. Crum NF, Riffenburgh RH, Wegner S. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006, 41:194-200.
16. Mocroft A, Brettle R, Kirk O. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002, 16:1663-1671.
17. Baker JV, Peng G, Rapkin J. Poor initial CD4 cell+recovery with antiretroviral therapy prolongs immune depletion and increases risk of AIDS and non-AIDS diseases. JAIDS 2008, 48:541-546.
18. Bautista-Arredondo S, Gadsden P, Harris JE, Bertozzi SM. Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS 2008, 22((Suppl. 1)):S67-S74.
19. 2008, 129-159. Joint United Nations Programme on HIV/AIDS (UNAIDS)., Treatment and care: unprecedented progress, remaining challenges. Report on the global AIDS epidemic
20. Chequer P, Cuchi P, Mazin R, García Calleja JM. Access to antiretroviral treatment in Latin American countries and the Caribbean. AIDS 2002, 16((Suppl. 3)):S50-S57.
21. Bastos FI, Cáceres C, Galvao J, Veras MA, Castilho EA. AIDS in Latin America: assessing the current status of the epidemic and the ongoing response. Int J Epidemiol 2008, 37:729-737.
22. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology 2008, 3rd ed, Philadelphia, PA, USA, Lippincott, Williams & Wilkins
23. Robins J, Gail MG, Lubin JH. More on 'biased selection of controls for case-control analysis of cohort studies'. Biometrics 1986, 42:293-299.
24. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol 2008, 168:1073-1081.
25. McQueen MJ, Hawken S, Wang X. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
26. Kuller LH, Tracy R, Belloso WH. Inflammation and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
27. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg 2007, 31:632-643.
28. Mehta N, Reilly M. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials 2005, 6:5-24.
29. Stein JH, Klein MA, Bellehumeur JL. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257-262.
30. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426. D:A:D Study Group .
31. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22:1979-1991.
32. Bottecchia M, Garcia-Samaniego J, Soriano V. The implications of antiviral drugs with activity against hepatitis B virus and HIV. Curr Opin Infect Dis 2007, 20:621-628.
33. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006, 44((Suppl.)):S65-S70.
34. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. DAD Study Group.
35. Moore RD, Gebo KA, Lucas GM, Keruly JC. Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell cell count and HAART use status. Clin Infect Dis 2008, 47:1102-1104.
36. Crabtree-Ramirez B, Gómez Palacio M, Rodríguez Rivera V, Reyes-Terán G. Baseline characteristics of HIV-infected patients attending a National Institute of Health in Mexico City: evidence of late detection of HIV infection and the urgent need for efficient. Voluntary Counseling and Testing (VCT) programs. Mexico DF, Mexico, August 2008. [Abstract THPE0244]